What is the difference between Semaglutide and Tirzepatide?

Semaglutide is a GLP-1R monoagonist (~15-17% weight reduction). Tirzepatide is a dual GIP+GLP-1R co-agonist (twincretin, ~20-22% weight reduction). Tirzepatide adds GIPR activation which provides insulin sensitization, adipocyte fat oxidation, and synergistic GLP-1R amplification — driving superior weight loss efficacy. Both are available from QSC Peptides with ≥99% purity and free USA shipping.

Semaglutide vs Tirzepatide — Research Comparison

// Side-by-Side

Comparison Table

Property	Semaglutide	Tirzepatide
Drug Class	GLP-1R Monoagonist	Dual GIP+GLP-1R (Twincretin)
Receptors Targeted	GLP-1R only	GLP-1R + GIPR
Scaffold	GLP-1 modified + C18 FA	GIP-based 39-aa + C18 FA diacid
GLP-1R Affinity	~3× native GLP-1	~5× weaker than native (intentional)
GIPR Affinity	None	Native-like
Half-Life	~7 days	~5 days
Avg. Weight Reduction	~15–17%	~20–22%
HbA1c Reduction	~1.8%	~2.2%
Energy Expenditure ↑	Minimal	Moderate (GIPR)
Insulin Sensitization	Indirect (weight loss)	Direct (GIPR on adipocytes)
QSC Peptides Entry Price	$190 (10mg 10-vial)	$210 (15mg 10-vial)

// Key Differences

What GIPR Agonism Adds

The single key question in the Semaglutide vs Tirzepatide comparison: what does GIPR activation contribute?

What GIP Does in Tirzepatide

Adipocyte fat oxidation: GIPR on fat cells activates cAMP → PKA → HSL-mediated lipolysis, burning stored fat as fuel in addition to appetite suppression
Insulin sensitization: GIPR in adipose tissue enhances insulin receptor downstream signaling and GLUT4 translocation — providing direct insulin sensitivity improvement beyond weight loss
GLP-1R synergy: GIPR co-activation sensitizes GLP-1R signaling through incompletely understood mechanisms, amplifying the GLP-1 response
Central effects: GIPR in hypothalamus and brainstem contributes to energy intake reduction independent of GLP-1R